Skip to content

Study · Animal study (in vivo) · mouse · 2021

2 results

Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho/JngJ mice.

Bhatti JS, Tamarai K, Kandimalla R, Manczak M, Yin X, Ramasubramanian B, Sawant N, Pradeepkiran JA, Vijayan M, Kumar S, Reddy PH

Mitochondrion25 Feb 2021Cited by 24 (Europe PMC)

PMID33639273 (opens in a new tab)DOI10.1016/j.mito.2021.02.007 (opens in a new tab)PepBankPUB-33639273
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic TH mice, SS31 treatment restored mitochondrial functions in liver tissue.

    In plain wordsIn diabetic mice, SS31 restored mitochondrial functions in the liver.

    Peptide
    Elamipretide (SS-31)
    Outcome
    MixedMitochondrial functions in liver (H2O2 production, ATP generation, lipid peroxidation)
    Study

    mousen: not reported in source

    Diabetic TALLYHO/JngJ (TH) mice, liver tissue
    Comparator
    Untreated diabetic TH mice
    Outcome group
    Mitochondrial function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, SS31 treatment significantly reduced the mitochondrial abnormalities and restore mitochondrial functions in diabetic TH mice.
    2 context sentences
    Summary · context
    Also, the mitochondrial functions including H2O2 production, ATP generation, and lipid peroxidation were assessed in all the groups.
    Summary · context
    The 24 weeks old experimental animals were segregated into three groups: Non-diabetic controls (SWR/J mice), diabetic (TH mice) and, SS31 treated diabetic TH mice.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diabetic TH mice, SS31 treatment significantly reduced mitochondrial abnormalities in liver tissue.

    In plain wordsIn diabetic mice, SS31 reduced abnormalities in liver mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial abnormalities in dynamics and biogenesis genes in liver
    Study

    mousen: not reported in source

    Diabetic TALLYHO/JngJ (TH) mice, liver tissue
    Comparator
    Untreated diabetic TH mice
    Outcome group
    Mitochondrial function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, SS31 treatment significantly reduced the mitochondrial abnormalities and restore mitochondrial functions in diabetic TH mice.
    2 context sentences
    Summary · context
    The mRNA expression and Western blot analysis of mitochondrial dynamics (Drp1 and Fis1 - fission; Mfn1, Mfn2, and Opa1 -fusion), and biogenesis (PGC-1α, Nrf1, Nrf2, and TFAM) genes were significantly altered in diabetic TH mice.
    Summary · context
    The 24 weeks old experimental animals were segregated into three groups: Non-diabetic controls (SWR/J mice), diabetic (TH mice) and, SS31 treated diabetic TH mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.